Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ARCUTIS BIOTHERAPEUTICS, INC.

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
Listen to this Section


$21.82
-0.1350 ( -0.62% ) 263.6K

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Market Data


Open $21.82
Previous Close $21.95
Volume 263.6K
Market Cap $2.75B
Day Range $21.77 - $22.17
52 Week Range $12.72 - $31.77
Shares Outstanding 125.08M
Change % -0.62%
Net Change ▼ -0.1350
Insider Ownership -0.03%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2020
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -110,519.00

Date Type Amount Purchased Purchaser
2024-08-05 Sale -6614.00 Welgus Howard G.
2024-07-02 Sale -5681.00 Welgus Howard G.
2024-06-18 Sale -10139.00 CHAUDHURI BHASKAR
2024-06-18 Sale -10139.00 Gilbert Halley E
2024-06-18 Sale -10139.00 LIN SUE-JEAN
2024-06-18 Sale -10139.00 Krishnamohan Neha
2024-06-18 Sale -10139.00 Curran Terrie
2024-06-18 Sale -10139.00 Heron Patrick J
2024-06-18 Sale -10139.00 Welgus Howard G.
2024-06-18 Sale -10139.00 Leonard Keith R

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Nov 10, 2025
4 Insider transactions 1 Nov 10, 2025
4 Insider transactions 1 Nov 05, 2025
4 Insider transactions 1 Nov 05, 2025
4 Insider transactions 1 Nov 05, 2025
4 Insider transactions 1 Nov 05, 2025
4 Insider transactions 1 Nov 05, 2025
4 Insider transactions 1 Oct 30, 2025
8-k 8K-related 14 Oct 28, 2025
10-q Quarterly Reports 69 Oct 28, 2025

Latest News


× Before browsing our site, please accept our cookies policy